These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 30178686)

  • 21. The biology of saphenous vein graft occlusion: etiology and strategies for prevention.
    Bryan AJ; Angelini GD
    Curr Opin Cardiol; 1994 Nov; 9(6):641-9. PubMed ID: 7819622
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Preoperative neutrophil-lymphocyte ratio and saphenous vein graft patency after coronary artery bypass grafting.
    Taşoğlu I; Turak O; Nazli Y; Ozcan F; Colak N; Sahin S; Kavasoglu K; Genc B; Sert D; Karahan M; Cicek O; Ecevit A
    Clin Appl Thromb Hemost; 2014 Nov; 20(8):819-24. PubMed ID: 23580624
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Red blood cell distribution width in saphenous vein graft disease.
    Akyel A; Celik IE; Oksüz F; Cay S; Karadeniz M; Kurtul A; Ocek AH; Murat SN
    Can J Cardiol; 2013 Apr; 29(4):448-51. PubMed ID: 22926040
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Coronary artery bypass graft disease.
    Nwasokwa ON
    Ann Intern Med; 1995 Oct; 123(7):528-45. PubMed ID: 7661498
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Current percutaneous treatment strategies for saphenous vein graft disease.
    Marmagkiolis K; Grines C; Bilodeau L
    Catheter Cardiovasc Interv; 2013 Sep; 82(3):406-13. PubMed ID: 22777812
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Gene therapy and coronary artery bypass grafting: current perspectives.
    George SJ; Channon KM; Baker AH
    Curr Opin Mol Ther; 2006 Aug; 8(4):288-94. PubMed ID: 16955691
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prediction of Major Adverse Cardiovascular Events and Slow/No-Reflow by Virtual Histology Imaging After Percutaneous Interventions on Saphenous Vein Grafts.
    Liu Y; Li CP; Wang YY; Dong YN; Liu HW; Xiao JY; Gao MD; Wang JX; Li XW; Zhang N; Ma J; Gao J
    Angiology; 2020 Mar; 71(3):263-273. PubMed ID: 31867979
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Modulation of phosphatidylinositol 3-kinase signaling reduces intimal hyperplasia in aortocoronary saphenous vein grafts.
    Hata JA; Petrofski JA; Schroder JN; Williams ML; Timberlake SH; Pippen A; Corwin MT; Solan AK; Jakoi A; Gehrig TR; Kontos CD; Milano CA
    J Thorac Cardiovasc Surg; 2005 Jun; 129(6):1405-13. PubMed ID: 15942585
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Fractional flow reserve-guided coronary artery bypass grafting: can intraoperative physiologic imaging guide decision making?
    Ferguson TB; Chen C; Babb JD; Efird JT; Daggubati R; Cahill JM
    J Thorac Cardiovasc Surg; 2013 Oct; 146(4):824-835.e1. PubMed ID: 23915918
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antithrombotic therapy in the coronary vein graft patient.
    Israel DH; Adams PC; Stein B; Chesebro JH; Fuster V
    Clin Cardiol; 1991 Apr; 14(4):283-95. PubMed ID: 2032405
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Gene delivery to aortocoronary saphenous vein grafts in a large animal model of intimal hyperplasia.
    Petrofski JA; Hata JA; Gehrig TR; Hanish SI; Williams ML; Thompson RB; Parsa CJ; Koch WJ; Milano CA
    J Thorac Cardiovasc Surg; 2004 Jan; 127(1):27-33. PubMed ID: 14752409
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Patency of the saphenous vein conduit anastomosed to the aortic dacron graft.
    Kara I; Koksal C; Boyacioglu K; Ay Y; Yanartas M; Metin Esen A
    J Cardiovasc Surg (Torino); 2013 Oct; 54(5):647-52. PubMed ID: 24002395
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Progression from stenosis to occlusion in the proximal native coronary artery after coronary artery bypass grafting.
    Tanaka A; Ishii H; Oshima H; Shibata Y; Tatami Y; Osugi N; Ota T; Kawamura Y; Suzuki S; Usui A; Murohara T
    Heart Vessels; 2016 Jul; 31(7):1056-60. PubMed ID: 26174429
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Coronary artery bypass graft: why is the saphenous vein prone to intimal hyperplasia?
    Sur S; Sugimoto JT; Agrawal DK
    Can J Physiol Pharmacol; 2014 Jul; 92(7):531-45. PubMed ID: 24933515
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Arterial and venous conduits for coronary artery bypass. A current review.
    Cooper GJ; Underwood MJ; Deverall PB
    Eur J Cardiothorac Surg; 1996; 10(2):129-40. PubMed ID: 8664004
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Percutaneous Coronary Intervention in Native Coronary Arteries Versus Bypass Grafts in Patients With Prior Coronary Artery Bypass Graft Surgery: Insights From the Veterans Affairs Clinical Assessment, Reporting, and Tracking Program.
    Brilakis ES; O'Donnell CI; Penny W; Armstrong EJ; Tsai T; Maddox TM; Plomondon ME; Banerjee S; Rao SV; Garcia S; Nallamothu B; Shunk KA; Mavromatis K; Grunwald GK; Bhatt DL
    JACC Cardiovasc Interv; 2016 May; 9(9):884-93. PubMed ID: 27085582
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Role of smooth muscle cells in coronary artery bypass grafting failure.
    Wadey K; Lopes J; Bendeck M; George S
    Cardiovasc Res; 2018 Mar; 114(4):601-610. PubMed ID: 29373656
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of the size mismatch between saphenous vein graft and coronary artery on graft patency.
    Yamane Y; Uchida N; Okubo S; Morimoto H; Mukai S
    Gen Thorac Cardiovasc Surg; 2017 Jan; 65(1):25-31. PubMed ID: 27485249
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Association between paraoxonase activity and late saphenous vein graft occlusion in patients with coronary artery bypass grafting.
    Cagirci G; Cay S; Karakurt O; Yazihan N; Aydin C; Acikel S; Dogan M; Kilic H; Topaloglu S; Aras D; Akdemir R
    Kardiol Pol; 2009 Oct; 67(10):1063-8. PubMed ID: 20017071
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Intensive versus moderate atorvastatin therapy and one-year graft patency after CABG: Rationale and design of the ACTIVE (Aggressive Cholesterol Therapy to Inhibit Vein Graft Events) randomized controlled trial (NCT01528709).
    Kulik A; Abreu AM; Boronat V; Ruel M
    Contemp Clin Trials; 2017 Aug; 59():98-104. PubMed ID: 28611006
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.